Partnering is part of our strategy to bring new and innovative products to patients in our regions.
We remain focused on building an increasingly diverse portfolio through investments in internal R&D, partnerships and strategic acquisitions.
Our broad geographic presence, strong manufacturing and commercial capabilities, deep knowledge of local markets and long-standing reputation makes us uniquely positioned to attract partners. This enables us to grow our portfolio and increase patients’ access to differentiated medicines across our markets, putting better health within reach, every day.
Contact us: https://www.hikma.com/contact/
Partnership highlights
Bio-Thera Solutions, Ltd.
Monoclonal Antibody
Boehringer Ingelheim
Respiratory Diseases
Celltrion
Biological, Oncology and Rheumatology
Junshi Biosciences
Innovative Anti-PD-1 Monoclonal Antibody
Vifor Pharma
Blood and blood-forming and anti-anemic
Newsroom
All news stories
Latest partnership news
Featured
Hikma acquires the rights to a portfolio of Takeda brands for the MENA region
Press Release, Product
19 December 2024
- Hikma signs an exclusive agreement with DGI Group to bring Claritag® to the MENA region Press Release, Business Development 19 November 2025 Hikma signs an exclusive agreement with DGI Group to bring Claritag® to the MENA region
- Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA Press Release, Business Development 06 October 2025 Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA
- Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA Press Release, Business Development 09 April 2025 Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA
- Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE Press Release, Business Development 30 January 2025 Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE
Related content